c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study

被引：0
|
作者：
Bar, J. [1 ]
Baijal, S. [2 ]
Luo, A. [3 ]
Zhang, N. [4 ]
Ratajczak, C. [5 ]
Ansell, P. J. [6 ]
Lu, S. [7 ]
Camidge, D. R. [8 ]
机构：
[1] Univ Hosp Birmingham, Sheba Med Ctr, Jusidman Canc Ctr, Ramat Gan, Israel
[2] NHS Fdn Trust, Med Oncol Dept, Birmingham, W Midlands, England
[3] AbbVie Inc, Oncol Stat, Chicago, IL USA
[4] AbbVie Inc, CDx Strategy & Precis Med, Chicago, IL USA
[5] AbbVie Inc, Oncol Early Dev, Chicago, IL USA
[6] AbbVie Inc, Precis Med Oncol, Chicago, IL USA
[7] Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[8] Univ Colorado, Med Oncol, Ctr Canc, Aurora, CO USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1379P
引用
收藏
页码：S866 / S866
页数：1
相关论文
共 50 条
  • [21] A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
    Waqar, Saiama N.
    Redman, Mary W.
    Arnold, Susanne M.
    Hirsch, Fred R.
    Mack, Philip C.
    Schwartz, Lawrence H.
    Gandara, David R.
    Stinchcombe, Thomas E.
    Leighl, Natasha B.
    Ramalingam, Suresh S.
    Tanna, Saloni H.
    Raddin, Ryan S.
    Minichiello, Katherine
    Bradley, Jeffrey D.
    Kelly, Karen
    Herbst, Roy S.
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL LUNG CANCER, 2021, 22 (03) : 170 - 177
  • [22] METRIX: International real-world study of c-Met protein overexpression in patients with non-small cell lung cancer
    Horinouchi, H.
    Xu, Z.
    Prince, S. Savic
    De la Iglesia, P.
    Enrico, D. H.
    Desmeules, P.
    Koslucher, A.
    Ansell, P. J.
    Thiebaut, R.
    Hader, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S1643 - S1644
  • [23] Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
    Yang, J-J.
    Zhang, Y.
    Wu, L.
    Hu, J.
    Wang, Z-H.
    Chen, J-H.
    Fan, Y.
    Lin, G.
    Wang, Q-M.
    Yao, Y.
    Zhao, J.
    Chen, Y.
    Fang, J.
    Song, Y.
    Zhang, W.
    Cheng, Y.
    Guo, R-H.
    Li, X-Y.
    Li, A-N.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [24] Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
    Baljevic, Muhamed
    Zaman, Shadia
    Baladandayuthapani, Veerabhadran
    Lin, Yan Heather
    de Partovi, Claudia Morales
    Berkova, Zuzana
    Amini, Behrang
    Thomas, Sheeba K.
    Shah, Jatin J.
    Weber, Donna M.
    Fu, Min
    Cleeland, Charles S.
    Wang, Xin Shelley
    Stellrecht, Christine M.
    Davis, Richard E.
    Gandhi, Varsha
    Orlowski, Robert Z.
    ANNALS OF HEMATOLOGY, 2017, 96 (06) : 977 - 985
  • [25] Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
    Muhamed Baljevic
    Shadia Zaman
    Veerabhadran Baladandayuthapani
    Yan Heather Lin
    Claudia Morales de Partovi
    Zuzana Berkova
    Behrang Amini
    Sheeba K. Thomas
    Jatin J. Shah
    Donna M. Weber
    Min Fu
    Charles S. Cleeland
    Xin Shelley Wang
    Christine M. Stellrecht
    Richard E. Davis
    Varsha Gandhi
    Robert Z. Orlowski
    Annals of Hematology, 2017, 96 : 977 - 985
  • [26] Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
    Goldman, Jonathan W.
    Horinouchi, Hidehito
    Cho, Byoung Chul
    Tomasini, Pascale
    Dunbar, Martin
    Hoffman, David
    Parikh, Apurvasena
    Blot, Vincent
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J).
    Falchook, Gerald Steven
    Kurzrock, Razelle
    Amin, Hesham M.
    Fu, Siqing
    Piha-Paul, Sarina Anne
    Janku, Filip
    Zheng, Hongxia
    Sarholz, Barbara
    Johne, Andreas
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)
    Orlowski, Robert Z.
    Zaman, Shadia
    Thomas, Sheeba K.
    Alexanian, Raymond
    Shah, Jatin J.
    Weber, Donna M.
    Wang, Michael
    Holloway, Ashley N.
    Baladandayuthapani, Veerabhadran
    Lin, Heather Yan
    Fu, Min
    Stellrecht, Christine M.
    de Partovi, Claudia Morales
    Gandhi, Varsha
    BLOOD, 2013, 122 (21)
  • [29] Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study
    Hu, Xingsheng
    Cui, Xinge
    Wang, Ziping
    Liu, Yunpeng
    Luo, Ying
    Zhong, Wei
    Zhao, Hui
    Yao, Mengxing
    Jiang, Da
    Wang, Mingxia
    Chen, Minjiang
    Zheng, Xin
    Ding, Lieming
    Wang, Yang
    Yuan, Xiaobin
    Wu, Pengxiang
    Hu, Bei
    Han, Xiaohong
    Shi, Yuankai
    BMC CANCER, 2023, 23 (01)
  • [30] Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study
    Xingsheng Hu
    Xinge Cui
    Ziping Wang
    Yunpeng Liu
    Ying Luo
    Wei Zhong
    Hui Zhao
    Mengxing Yao
    Da Jiang
    Mingxia Wang
    Minjiang Chen
    Xin Zheng
    Lieming Ding
    Yang Wang
    Xiaobin Yuan
    Pengxiang Wu
    Bei Hu
    Xiaohong Han
    Yuankai Shi
    BMC Cancer, 23
12345